Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus EPIFOAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus EPIFOAM.
ARAZLO vs EPIFOAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Epinephrine is a sympathomimetic amine that acts as a non-selective agonist at alpha- and beta-adrenergic receptors. It causes vasoconstriction, bronchodilation, and increased heart rate and contractility.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Not applicable; EPIFOAM is a topical foam containing pramoxine hydrochloride 1% and aluminum acetate, used for hemorrhoidal symptoms. No systemic dosing.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
2-3 hours (terminal elimination half-life); clinically, this supports every 4-6 hour dosing intervals for consistent effect.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily hepatic metabolism to inactive glucuronide conjugates; renal excretion of metabolites accounts for ~80% of elimination, with ~15% biliary/fecal. Less than 5% excreted unchanged in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid